Venkatesan Jay 4/A
4/A · Elicio Therapeutics, Inc. · Filed Jan 2, 2025
Insider Transaction Report
Form 4/AAmended
Venkatesan Jay
Director
Transactions
- Purchase
Common Warrants
2024-06-28+50,000→ 50,000 totalExercise: $5.00→ Common Stock (50,000 underlying) - Purchase
Pre-Funded Warrants
2024-06-28$4.99/sh+50,000$249,500→ 50,000 totalExercise: $0.01→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
- [F2]The Common Warrants expire on July 1, 2029.
- [F3]On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein.
- [F4]Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
- [F5]The Pre-Funded Warrants do not have an expiration date.